semaglutide for quitting smoking May Ease Tobacco Use, Study Suggests 🚭 Thinking about quitting smoking?

Clinical evidence supports GLP-1 receptor agonists for weight loss, with average reductions of 1015% body weight over 68 weeks

There is also a caution regarding diabetic retinopathy, particularly in patients using insulin

Suitable for repeated measured use

Similar results were seen if participants were prescribed GLP-1 agonist medication for obesity rather than diabetes: 5.9 percent versus 3.2 percent of body weight lost

The fat cell experiences simultaneous enhancement of fat breakdown and reduction of fat formation

Tobacco has been linked to increases in heart disease, cancers, and premature mortality, among others, Glickman expalined